Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics is a drug discovery company that uses computational chemistry and machine learning to design molecules that modulate protein behaviour — a technical capability that attracts pharma partners willing to fund its research through upfront payments, milestones, and royalties. The company operates in an asset-light model: it discovers and develops early-stage drug candidates and partners with larger pharmaceutical firms to advance them through clinical trials and commercialisation. Its shares (NASDAQ: RLAY) trade in a sector where capital intensity varies wildly, and Relay’s model attempts to mitigate that variance by shifting funding risk to partners who see the potential in its technology.

The computational approach to drug discovery

Relay’s core technology is computational chemistry — using algorithms and machine learning to predict how small molecules will interact with and modulate protein targets. In cancer biology and other indications, many disease-driving proteins have been considered “undruggable”: conventionally designed molecules cannot bind to them in a way that produces a therapeutic effect. Relay’s approach is to model protein structures at atomic resolution, simulate how candidate molecules might bind, and iterate computationally to identify compounds with the desired properties. The company then synthesises and tests the most promising candidates experimentally.

This matters because it compresses the discovery cycle and reduces the number of failed wet-lab experiments required to find viable candidates. In a field where a single drug programme can consume a decade and hundreds of millions of dollars before it even reaches the clinic, shaving years off the discovery phase and reducing dead-end synthesis runs can add meaningful value.

Relay was founded by scientists from Cambridge and MIT who had developed the underlying computational models. The team built the capability with an eye toward applying it to validated cancer targets that large pharma knew mattered but had struggled to drug. This positioning — solving problems that matter to pharma — became the foundation of Relay’s partnership strategy.

How partnerships fund the science

Relay does not try to develop drugs all the way to market itself. The company identifies targets, builds a small internal team to generate early-stage compounds, and then seeks partnerships with larger pharmaceutical firms. Those partners provide upfront funding (often $20 million to $100 million per agreement), pay milestone fees as the compounds progress, and commit royalties on any drugs that reach commercialisation. This model transfers the massive costs and risks of late-stage development — pivotal clinical trials, regulatory approval, manufacturing scale-up — to partners with those capabilities.

The strategy has worked: Relay has partnerships with major pharma firms who believe in its technology enough to commit capital. Each partnership provides a revenue stream (in the form of upfront and milestone payments) that funds the company’s core computational platform and discovery efforts. Because Relay is not funding the full development cost of each programme, it can take on multiple shots at once without the balance-sheet weight that a fully integrated biotech would carry.

The capital narrative is that Relay extracts value by solving the hardest part of drug discovery — target validation and early-stage compound design — and letting partners absorb the downstream costs. If the science is sound and the partnerships generate both milestones and eventual royalties, the model is profitable and capital-efficient.

What the company must prove

The critical tests are whether Relay’s computational approach actually reduces the failure rate in drug discovery and whether the molecules it identifies have the properties that move pharma partners forward in the clinic. Early data — compounds from Relay partnerships that have advanced into human trials — is the market’s way of judging whether the technology is a genuine shortcut or a neat-sounding idea that does not move the needle in practice.

Relay also must maintain the strength and quality of its partnerships. If a major pharma partner deprioritises a programme or pivots away from oncology, the associated milestone and royalty revenue disappears. The company is not dependent on any one partner, but a pattern of partnerships losing momentum would signal that the market has lost confidence in Relay’s technology platform.

The competitive and commercial landscape

Relay operates in an increasingly crowded space of computational-chemistry and structure-based-design companies. Other firms use similar techniques; some are backed by large pharma themselves (as corporate venture arms), which creates competition for partnerships. The differentiation, if it exists, lies in the quality of the target selection, the soundness of the chemistry, and the track record of generating compounds that actually work in the clinic.

Larger pharma companies also have built or acquired computational chemistry capabilities in-house, which reduces their dependency on external partners like Relay. The competitive advantage of a focused external firm is that it can concentrate expertise and avoid the bureaucracy of large organisations, but that advantage is fragile and depends on continued execution.

Funding and investor focus

Relay’s financial position depends on partnership milestones and upfront fees, not product sales, which creates lumpy revenue and makes the company sensitive to the timing and amount of partnership deals. The balance sheet matters for runway between partnership agreements. The company is not yet profitable on an earnings basis, so the investment thesis is that partnerships will materially expand and that early-stage programmes will advance into clinical development, generating both milestone revenue and future royalties.

Investors watch a few key metrics: the number of active partnerships and the aggregate potential milestone value and royalty rates of those partnerships (which is disclosed in 10-K filings); the number of compounds advancing into the clinic; the composition of the target portfolio (are the targets addressing validated, high-value indications?); and gross-margin trends as the mix of revenue between upfront payments and milestones shifts. The research risk is high — compounds fail in the clinic despite strong early data — but the partnership model puts much of the capital risk onto pharma, not onto Relay’s balance sheet.

How to research Relay as an investor

Start with the 10-K (SEC CIK 0001812364), which lists each significant partnership agreement, the target indication, the upfront payment, and the potential milestone structure. Read the risk factors carefully, as they will highlight partner-concentration risk and clinical development risks. Watch quarterly earnings releases for commentary on pipeline progress and any new partnership announcements. Follow the regulatory filings on Relay’s partnerships to understand when key milestones are expected (often disclosed in SEC filings). Understand that this is a venture-capital-like bet dressed in public-market clothes: most value comes from compounds that eventually generate royalties, and that future is years and many clinical trials away.